surmount‑5 biomarker data
Semaglutide Is Overrated - SURMOUNT-5 Shows Tirzepatide Wins
In the SURMOUNT-5 trial tirzepatide produced a median BMI reduction of 15.7 points versus 11.3 points with semaglutide, demonstrating a clear superiority in weight loss and metabolic impact. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare